Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;3(1):a001115.
doi: 10.1101/mcs.a001115.

ALK: a tyrosine kinase target for cancer therapy

Affiliations
Review

ALK: a tyrosine kinase target for cancer therapy

Vijaykumar R Holla et al. Cold Spring Harb Mol Case Stud. 2017 Jan.

Abstract

The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL). Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC. In other tumors, ALK copy-number gains and activating ALK mutations have been described. Dramatic and often prolonged responses are seen in patients with ALK alterations when treated with ALK inhibitors. Three of these-crizotinib, ceritinib, and alectinib-are now FDA approved for the treatment of metastatic NSCLC positive for ALK fusions. However, the emergence of resistance is universal. Newer ALK inhibitors and other targeting strategies are being developed to counteract the newly emergent mechanism(s) of ALK inhibitor resistance. This review outlines the recent developments in our understanding and treatment of tumors with ALK alterations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Anaplastic lymphoma kinase (ALK) signaling: Pathway figure that depicts normal activation of ALK through ligand binding. Receptor phosphorylation stimulates downstream signaling through the PI3K/AKT, MAPK/ERK, and STAT3 pathways. These signaling cascades can contribute to increased cancer cell growth, survival, and metastasis.
Figure 2.
Figure 2.
Activating mutations in ALK: COSMIC (tumor only) frequencies of ALK mutations with published literature on functional and/or therapeutic significance. mRNA sequence depicts full reference sequence of ALK (NM_004304) with exon numbers marked. ALK protein sequence (0–1620 amino acids) shows different functional domains (MAM1, LDL, MAM2, Gly-rich, and kinase domain) with starting and ending amino acid numbers (UniProt). COSMIC frequency units (black circles and numbers in parentheses) refer to the number of tumor samples with a particular single-nucleotide variant (SNV) found in COSMIC. The SNVs without the black circles are referenced in literature that is not recorded in COSMIC.

References

    1. Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, et al. 2015. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer 113: 1730–1734. - PMC - PubMed
    1. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, Racaud-Sultan C, Allouche M, Campo E, Delsol G, et al. 2004. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23: 6071–6082. - PubMed
    1. Bagci O, Tumer S, Olgun N, Altungoz O. 2012. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. Cancer Lett 317: 72–77. - PubMed
    1. Bavi P, Jehan Z, Bu R, Prabhakaran S, Al-Sanea N, Al-Dayel F, Al-Assiri M, Al-Halouly T, Sairafi R, Uddin S, et al. 2013. ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer 109: 2735–2743. - PMC - PubMed
    1. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, et al. 2010. Activity of Pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68: 264–268. - PubMed